All News

ICYMI: Males respond better than females? Ixekizumab trials in #PSA - 676 pts in Two Phase 3 RCTs - females had lower response rates than males in all measures (ACR20/50/70; MDA; DAPSA) F had ⬆️HAQ, enthesitis, but ⬇️CRP https://t.co/sjVJZ8uQA3 https://t.co/l7B2ICZWaJ

Links:

Dr. John Cush RheumNow ( View Tweet)
TNR,PSA,journal,0412

Now Available: TNR - Psoriatic Arthritis Journal Club

d Jack Cush, MD

A recording of this week’s Tuesday Night Rheumatology is now available. This outstanding webinar featured a robust discussion of the EXCEED study and Discover-2 trial, with Drs. Philip Mease, Peter Nash, Jack Cush and Rachel Tate.

Read Article
RheumNow Podcast square

Male vs. Female Responders (4.15.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 

Read Article
Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor https://t.co/CfAjvc9XWg https://t.co/RaD5qqPM3a

Links:

Dr. John Cush RheumNow ( View Tweet)
child.guttate.psoriasis

Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor

d MedPage Today

Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.

Read Article
Ixekizumab in 1401 #PSA pts w/ 2248 Pt-Yrs exposure showed Serious AE in 134 pts. Most common AEs were nasopharyngitis & URI. Incidence of SAE (≤1.2/100PY), cancer (0.7/100PY), IBD (0.1/00PY), depression (1.6/100PY) were low. #PSAlways https://t.co/YGGj4XCQDM

Links:

Dr. John Cush RheumNow ( View Tweet)

2020 Pt preferences survey- 137 #PsA pts most took TNFi (30%), IL-17i (20%), MTX (10%). From 2018 to 2020 a signif incr in IL-17i & PDE4 inhib. Pts want Rx for damage (80%), ADL (71%), & pain (70%) https://t.co/2dyIuQubh5 https://t.co/sFbtRj0Lbv

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Review of 5 trials shows ixekizumab with higher rates of complete skin & nail clearance compared H2H against to etanercept, guselkumab, ustekinumab, and adalimumab (Data from IXORA-R, IXORA-S, UNCOVER-2, UNCOVER-3, & SPIRIT-H2H trials https://t.co/t5wrmE3nbK #PsA #PsAlways https://t.co/MQjgktOZWR

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast square

RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.

Read Article
Psoriasis Severe legs sara

Differences in Biologic Persistence in Psoriasis and Psoriatic Arthritis

d Jack Cush, MD

Administrative claims analysis of biologic use in psoriasis (PsO) and psoriatic arthritis (PsA) in French health insurance databases shows that despite widespread biologic use, overall drug persistence (beyond 3 years) was low for PsO and PsA biologics.

Read Article
Ask Cush Anything! Have a rheumatology question or case for Dr. Cush? Submit it here and we may feature it on an upcoming podcast. https://t.co/KgPIeScthr https://t.co/nk4re9mlcH

Links:

Dr. John Cush RheumNow ( View Tweet)
"Remember bony growth is a feature of the PsA joint and one potential way in which IL17s may target the disease." Dr. B. Kirkham discusses potential synergistic activity of IL17A and TNFi in the SpA joint. #RNL2022 @RheumNow https://t.co/L9uZqoen2w
Dr. Rachel Tate uptoTate ( View Tweet)
IL-17i - Good Long term safety profile and low malignancy risk Best efficacy for nail psoriasis @RheumNow #RNL2022 https://t.co/8T7wAGJChF
Robert B Chao, MD doctorRBC ( View Tweet)
#ClinicalPearl Fun fact According to Dr Strober IL17i have BEST effects on nail involvement in #psoriasis. I didn’t know. often need ⬆️dose over time #RNL2022 @RheumNow https://t.co/Y9U9c4M03j
Janet Pope Janetbirdope ( View Tweet)
Run down on IL-17 inhibitors by Dr Strober @BruceStrober #RNL2022 https://t.co/mqXvfJGhij
Dr. John Cush RheumNow ( View Tweet)
Role of IL17 blockers in creating dysbiosis (expansion of Candida), could that be one of the reasons explaining its effect in SpA and PsA?!! Jose Scher @RheumNow #Rnl2022 https://t.co/AyGgNiDVJ9
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Cellular source of IL17 in SpA Bruce Kirkham @RheumNow #Rnl2022 https://t.co/vDMks0RtBb
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Synergetic effect of IL17 and TNF in PSA. Bruce Kirkham @RheumNow #Rnl2022 https://t.co/acfqiluJWR
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dr. B. Kirkman reviews research and development timeline for IL17A. I've started explaining this trajectory to patients when discussing "newer" drugs to market that have been around since I was in elementary school. #RNL2022 @RheumNow https://t.co/TgaOYmkBO4
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. Kirkman reviews IL12, IL23, and IL17s. #RNL2022 @RheumNow https://t.co/nFHBzrdz2D
Dr. Rachel Tate uptoTate ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.

×